Barbara M.
- Country
- Italy
- Department
- U.O. Oncologia Medica
Research Overview
- Evaluation of Administration Route Preference for Nivolumab and Relatlimab in Melanoma Patients: Subcutaneous Versus Intravenous Delivery
- Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
- Adjuvant Pembrolizumab Versus Placebo in High-Risk Stage III Melanoma Post-Resection: A Randomized, Double-Blind Phase 3 EORTC Trial
Data & Insights
Has run more than one trial at 107 of 258 partner sites.
Specializations
Melanoma Research
The investigator specializes in various stages of melanoma treatment, with particular focus on adjuvant therapy approaches and innovative treatment strategies for both early and advanced stages.
- Stage II-IV Melanoma Management
- BRAF V600 Mutation-Positive Cases
- Adjuvant Immunotherapy Applications
Their work encompasses both resectable and metastatic disease scenarios, incorporating various administration routes for immunotherapy treatments.
Immunotherapy Innovation
The investigator focuses on advancing immunotherapeutic approaches, particularly exploring combinations of targeted therapies and immune checkpoint inhibitors.
- PD-1 Inhibitor Treatments
- Combination Immunotherapy Protocols
- Novel Administration Routes
Their research includes evaluation of both intravenous and subcutaneous administration methods for immunotherapy regimens.
Additional Oncology Focus
The investigator's expertise extends to other significant areas of oncological research, including rare and aggressive cancer types.
- Cutaneous Squamous Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Pre-operative Treatment Strategies
Their work includes investigation of novel therapeutic approaches for resectable malignancies and optimization of treatment timing.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.